Pyrazapon (CI-683): a new antianxiety agent.
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D001007:Anxiety / Q000188:drug therapy*; D001381:Azepines / Q000494:pharmacology* / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002707:Chlordiazepoxide / Q000494:pharmacology; D003220:Conflict, Psychological; D003975:Diazepam / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D004569:Electroencephalography; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D000882:Haplorhini; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008026:Ligation; D008124:Locomotion / Q000187:drug effects; D008251:Macaca; D008297:Male; D051379:Mice; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D004856:Postural Balance / Q000187:drug effects; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D012653:Self Stimulation; D013045:Species Specificity; D014149:Tranquilizing Agents / Q000494:pharmacology* / Q000627:therapeutic use
D000927:Anticonvulsants; D001381:Azepines; D011720:Pyrazoles; D014149:Tranquilizing Agents; D002707:Chlordiazepoxide; D003975:Diazepam; D010433:Pentylenetetrazole